Interim Results for the Six Months Ended 30 June 2024
September 23, 2024 08:42 ET
|
OXB
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration...
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
September 02, 2024 07:00 ET
|
Oxford BioMedica plc
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and...
Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight
August 05, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight The BCL-2 inhibitors market is anticipated to...
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
July 18, 2024 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im zweiten Quartal um +11% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +19% (kWk, +17% USD) Das Umsatzwachstum...
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
July 18, 2024 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RCRésultats du deuxième trimestre (T2)Chiffre d’affaires net en hausse de +11% (tcc1, +9% USD) et du résultat opérationnel core, de +19% (tcc, +17% USD) La...
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
July 18, 2024 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders
July 17, 2024 10:51 ET
|
Halper Sadeh LLC
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
Oxford Biomedica announces CFO transition
July 17, 2024 07:06 ET
|
Oxford BioMedica plc
Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”,...
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG – MOR
July 16, 2024 16:52 ET
|
Monteverde & Associates PC
NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders
July 08, 2024 08:53 ET
|
Halper Sadeh LLC
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...